Preparing for the 2020-2021 influenza season

被引：4
作者：
de St. Maurice, Annabelle [1 ]
Martin-Blais, Rachel [1 ]
Halasa, Natasha [2 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Pediat Infect Dis, Los Angeles, CA 90095 USA
[2] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Los Angeles, CA USA
来源：
PEDIATRIC TRANSPLANTATION | 2021年 / 25卷 / 05期
关键词：
covid; influenza; sars cov 2; vaccine; BALOXAVIR MARBOXIL; DOUBLE-BLIND; GUIDELINES; INHIBITORS; RECIPIENTS; CHILDREN; VACCINE;
D O I：
10.1111/petr.14025
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
The COVID-19 pandemic has altered health seeking behaviors and has increased attention to non-pharmaceutical interventions that reduce the risk of transmission of respiratory viruses including SARS-CoV-2 and influenza. While the potential impact of the COVID-19 pandemic on influenza is not fully known, in the Southern hemisphere influenza infection rates appear to be very low. Influenza vaccine efficacy for 2019-2020 season was comparable to prior season and influenza vaccine recommendations for pediatric immunizations remain similar to prior years. Influenza treatments continue to include neuraminidase inhibitors as well as baloxavir for treatment and in some instances prophylaxis.
引用
收藏
页数：8
相关论文
共 52 条
  • [1] [Anonymous], PINKBOOK INFLUENZA E
  • [2] [Anonymous], 2020, What you should know about COVID-19 to protect yourself and others
  • [3] [Anonymous], 2020, OPENING MIXING OSELT
  • [4] Australian Government Department of Health, 2020, INFL FLU
  • [5] Australian Government Department of Publica Health, 2020, AUSTR INFL SURV REP
  • [6] Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
    Baker, Jeffrey
    Block, Stanley L.
    Matharu, Balpreet
    Burleigh Macutkiewicz, Laura
    Wildum, Steffen
    Dimonaco, Sophie
    Collinson, Neil
    Clinch, Barry
    Piedra, Pedro A.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) : 700 - 705
  • [7] Balakrishnan VS, 2020, LANCET MICROBE, V1, pE199, DOI 10.1016/S2666-5247(20)30130-0
  • [8] Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial
    Beigel, John H.
    Aga, Evgenia
    Elie-Turenne, Marie-Carmelle
    Cho, Josalyn
    Tebas, Pablo
    Clark, Carol L.
    Metcalf, Jordan P.
    Ozment, Caroline
    Raviprakash, Kanakatte
    Beeler, Joy
    Holley, H. Preston, Jr.
    Warner, Stephanie
    Chorley, Carla
    Lane, H. Clifford
    Hughes, Michael D.
    Davey, Richard T., Jr.
    [J]. LANCET RESPIRATORY MEDICINE, 2019, 7 (11) : 941 - 950
  • [9] Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial
    Beigel, John H.
    Bao, Yajing
    Beeler, Joy
    Manosuthi, Weerawat
    Slandzicki, Alex
    Dar, Sadia M.
    Panuto, John
    Beasley, Richard L.
    Perez-Patrigeon, Santiago
    Suwanpimolkul, Gompol
    Losso, Marcelo H.
    McClure, Natalie
    Bozzolo, Dawn R.
    Myers, Christopher
    Holley, H. Preston, Jr.
    Hoopes, Justin
    Lane, H. Clifford
    Hughes, Michael D.
    Davey, Richard T.
    [J]. LANCET INFECTIOUS DISEASES, 2017, 17 (12) : 1255 - 1265
  • [10] Centers for Disease Control and Prevention , 2020, KEY FACTS SEAS FLU V
123456